HLN
HaleonBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
Bull thesis: sustained organic growth, clear margin progress from cost programs, and favorable analyst revisions drive multiple expansion toward the analyst high (~$14.39). Execution on product launches and pricing would crystallize this upside.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Demand softness in OTC categories or SKU delistings
Momentum
40
Value
59
Sentiment
66
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $11.39 · Bull $14.39 · Bear $8.99
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-06 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $11.03
Why
Momentum40 · Δ7d +37.7
Value59 · Δ7d +0.0
Sentiment66 · Δ7d -3.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
40
26% active weight
Current posture
7d trendImproving
Δ7d
+37.7
Δ21d
+35.6
Value
59
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
66
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.6
Δ21d
-8.8
Why this grade
Composite grade B. Momentum 40.3 / Value 58.9 / Sentiment 66.1
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$43.1B
Beta
0.39
Shares Out
4.4B
P/E (TTM) · Derived
20.0
P/S (TTM)
-
P/FCF (TTM)
23.47
Rev YoY
-0.3%
EPS YoY
+7965.6%
Gross Margin
+64.7%
Op Margin
+19.6%
Net Debt
$9.8B
Current Ratio
0.92
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology